CHARACTERIZATION OF PK/PD OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SLE

被引：3
|
作者：
Chia, Y. L. [1 ]
Tummala, R. [2 ]
Mai, T. [3 ,4 ]
Rouse, T.
White, W. [2 ]
Morand, E. F. [5 ]
Furie, R. [6 ]
机构：
[1] AstraZeneca, BioPharmaceut R&D, San Francisco, CA USA
[2] AstraZeneca, BioPharmaceut R&D, Gaithersburg, MD USA
[3] Genentech Inc, Clin Pharmacol & Modeling & Simulat, San Francisco, CA USA
[4] AstraZeneca, BioPharmaceut R&D, Gothenburg, Sweden
[5] Monash Univ, Ctr Inflammatory Dis Monash Hlth, Melbourne, Vic, Australia
[6] Zucker Sch Med Hofstra Northwell, Div Rheumatol, Great Neck, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0688
引用
收藏
页码：590 / 591
页数：2
相关论文
共 50 条
  • [41] Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
    Furie, Richard
    Khamashta, Munther
    Merrill, Joan T.
    Werth, Victoria P.
    Kalunian, Kenneth
    Brohawn, Philip
    Illei, Gabor G.
    Drappa, Jorn
    Wang, Liangwei
    Yoo, Stephen
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) : 376 - 386
  • [42] The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI-2K Responses and Continuous Measures of Activity As Outcome Measures
    Merrill, J. T.
    Furie, R.
    Werth, Victoria P.
    Khamashta, M.
    Drappa, J.
    Wang, L.
    Illei, G.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [43] Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A
    Young, Guy
    Callaghan, Michael U.
    Balasa, Vinod
    Soni, Amit
    Ahuja, Sanjay
    Roberts, Jonathan C.
    Simpson, Mindy L.
    Kizilocak, Hande
    Frick, Andrew
    Mokdad, Ali G.
    Xing, Shan
    Caicedo, Jorge
    HAEMOPHILIA, 2023, 29 (05) : 1234 - 1242
  • [44] Type I IFN, TLR7, MHC Class I, B Cell and OX40 Pathways Suppressed By Anifrolumab (anti-type I IFN receptor) in Moderate to Severe SLE Patients
    Streicher, Katie
    Wang, Jixin
    Brohawn, Philip Z.
    Higgs, Brandon W.
    Tummala, Raj
    Ranade, Koustubh
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [45] Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature
    Paolino, Giovanni
    Ramirez, Giuseppe A.
    Calabrese, Chiara
    Moroni, Luca
    Bianchi, Vittoria Giulia
    Bozzolo, Enrica P.
    Mercuri, Santo Raffaele
    Dagna, Lorenzo
    BIOMEDICINES, 2023, 11 (11)
  • [46] Assessment of Visual Field in Patients with Moderate-to-Severe Parkinson's disease (PD)
    Mehta, S.
    Syed, M.
    Naghizadehkashani, S.
    Shivok, K.
    Krisa, L.
    Matias, C.
    Wu, C.
    Liang, T.
    Sergott, R.
    Alizadeh, M.
    MOVEMENT DISORDERS, 2024, 39 : S500 - S501
  • [47] Characterization of gait in female patients with moderate to severe hallux valgus deformity
    Chopra, Swati
    Moerenhout, Kevin
    Crevoisier, Xavier
    SWISS MEDICAL WEEKLY, 2015, 145 : 15S - 15S
  • [48] Characterization of gait in female patients with moderate to severe hallux valgus deformity
    Chopra, S.
    Moerenhout, K.
    Crevoisier, X.
    CLINICAL BIOMECHANICS, 2015, 30 (06) : 629 - 635
  • [49] Characterization of the Phosphoproteome in SLE Patients
    Zhang, Xinzhou
    Ma, Hualin
    Huang, Jianrong
    Dai, Yong
    PLOS ONE, 2012, 7 (12):
  • [50] PK-PD of sertindole in schizophrenic patients
    Samara, E
    Granneman, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : OIIB2 - OIIB2
12345